Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC01-CD19 in Relapsed/Refractory Large B-Cell Lymphoma
NCT03880279Phase 2Withdrawn
- Sponsor
- Triumvira Immunologics
- Start
- May 2020
- Primary completion
- Apr 2022
- Modality
- CAR-T Cells
01
Overview
Phase 2, open-label, single-arm trial of TAC01-CD19 in diffuse large B-cell lymphoma (DLBCL), sponsored by Triumvira Immunologics. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Incidence of Adverse Events at 2 years. Planned start May 2020; status: withdrawn.
02
Drugs
TAC01-CD19
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03880279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880279.